


Docket No. 210119US0CONT



Image

1652
D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF William M. CANFIELD

SERIAL NO: 09/895,072

GAU: 1652

FILED: July 2, 2001

EXAMINER: Patterson

FOR: METHODS FOR PRODUCING HIGHLY PHOSPHORYLATED LYSOSOMAL HYDROLASES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Richard J. Chinn, Ph.D.
Registration No. 34,305




22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Daniel J. Pereira, Ph.D.
Registration No. 45,518

Docket No. 210119US0CONT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William M. CANFIELD

SERIAL NO: 09/895,072

GAU: 1652

FILED: July 2, 2001

EXAMINER: Patterson

FOR: METHODS FOR PRODUCING HIGHLY PHOSPHORYLATED LYSOSOMAL HYDROLASES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAYER & NEUSTADT, P.C.



Richard L. Chinn, Ph.D.
Registration No. 34,305



22850


Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Daniel J. Pereira, Ph.D.
Registration No. 45,518

FEB 12 2004

SHEET 1 OF 5

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 210119US0CONT	SERIAL NO. 09/895,072		
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT William M. CANFIELD					
		FILING DATE July 2, 2001		GROUP 1652			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AO	99/31117	06/24/99	WIPO	YES	NO	
	AP						
	AQ						
	AR						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
AS	Ke-Wei ZHAO, et al., "Purification and characterization of human lymphoblast N-acetylglucosamine-1-phosphotransferase", <i>Glycobiology</i> , Vol. 2, no. 2, pp. 119-125, 1992						
ATN	Takahiro NAGASE, et al., "Prediction of the Coding Sequences of Unidentified Human Genes. XV. The Complete Sequences of 100 New(cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> ", <i>DNA Research</i> , Vol. 6, pp. 337-345, 1999						
AU	XP-002226188, "KIAA1208 protein (Fragment)", From Takahiro NAGASE, et al., "Prediction of the Coding Sequences of Unidentified Human Genes. XV. The Complete Sequences of 100 New(cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> ", <i>DNA Research</i> , Vol. 6, pp. 337-345, 1999						
AV	XP-002226187, "Basic domain/leucine zipper transcription factor (Fragment)", From CORDES, et al., "The mouse segmentation gene kr encodes a novel basic domain-leucine zipper transcription factor" (1994), <i>Cell</i> , Vol. 7, No. 9, pp.1025-1034						
					<input type="checkbox"/> Additional References sheet(s) attached		
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
210119US0CONTSERIAL NO.
09/895,072

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT
William M. CANFIELDFILING DATE
July 2, 2001GROUP
1652

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						
	BM						
	BN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
	BO					
	BP					
	BQ					
	BR					
	BS					
	BT					
	BU					
	BV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

BW	Karen Gheesling MULLIS, et al., "Purification and Kinetic Parameters of Bovine Liver N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase", The Journal of Biological Chemistry, Vol. 269, No. 3, Issue of January 21, pp. 1718-1726, 1994	
BX	Jin Kyu LEE, et al., "Purification and Characterization of Human Serum N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase", Archives of Biochemistry and Biophysics, Vol. 319, No. 2, June 1, pp. 413-425, 1995	
BY	Theodore PAGE, et al., "Purification and characterization of human lymphoblast N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase", Glycobiology, Vol. 6, no. 6, pp. 619-626, 1996	
BZ	Thomas J. BARANSKI, et al., "Lysosomal Enzyme Phosphorylation", The Journal of Biological Chemistry, Vol. 267, No. 32, Issue of November 15, pp. 23342-23348, 1992	<input type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT		ATTY DOCKET NO. 210119US0CONT		SERIAL NO. 09/895,072	
		APPLICANT William M. CANFIELD			
		FILING DATE July 2, 2001		GROUP 1652	
		U.S. PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS SUB CLASS FILING DATE IF APPROPRIATE
	CA				
	CB				
	CC				
	CD				
	CE				
	CF				
	CG				
	CH				
	CI				
	CJ				
	CK				
	CL				
	CM				
	CN				
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	CO				
	CP				
	CQ				
	CR				
	CS				
	CT				
	CU				
	CV				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)					
CW	Ritva TIKKANEN, et al., "Several cooperating binding sites mediate the interaction of a lysosomal enzyme with phosphotransferase", The EMBO Journal, vol. 16, No. 22, pp. 6684-6693, 1997				
CX	Fumito MATSUURA, et al., "Human alpha-galactosidase A: characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cells", Glycobiology, vol. 8, no. 4, pp. 329-336, 1998				
CY	Shiroh MAGUCHI, et al., "Elevated Activity and Increased Mannose-6-phosphate in the Carbohydrate Moiety of Cathepsin D from Human Hepatoma", Cancer Research, Vol. 48, pp. 362-367, January 15, 1988				
CZ	Norman W. Barton, et al., "Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 1913-1916, March 1990	<input type="checkbox"/> Additional References sheet(s) attached			
Examiner				Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
210119US0SERIAL NO.
09/895,072

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT
William M. CANFIELDFILING DATE
July 2, 2001GROUP
1652

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	DA						
	DB						
	DC						
	DD						
	DE						
	DF						
	DG						
	DH						
	DI						
	DJ						
	DK						
	DL						
	DM						
	DN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
	DN					
	DP					
	DQ					
	DR					
	DS					
	DT					
	DU					
	DV					


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

DW	R.O. BRADY, et al., "Modifying Exogenous Glucocerebrosidase for Effective Replacement Therapy in Gaucher Disease", J. Inher. Metab. Dis., Vol. 17, (1994), pp. 510-519	
DX	Emil D. KAKKIS, et al., "Overexpression of the Human Lysosomal Enzyme α -L-Iduronidase in Chinese Hamster Ovary Cells", Protein Expression and Purification, Vol. 5, (1994), pp. 225-252	
DY	Ke-Wei ZHAO, et al., "Carbohydrate Structures of Recombinant Human α -L-Iduronidase Secreted by Chinese Hamster Ovary Cells", The Journal of Biological Chemistry, Vol. 272, No. 36, Issue of September 5, 1997, pp. 22758-22765	
DZ	Robin J. ZIEGLER, et al., "Correction of Enzymatic and Lysosomal Storage Defects in Fabry Mice by Adenovirus-Mediated Gene Transfer", Human Gene Therapy, Vol. 10, pp. 1667-1682, (July 1, 1999)	<input type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 210119US0		SERIAL NO. 09/895,072	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT William M. CANFIELD			
				FILING DATE July 2, 2001		GROUP 1652	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	EA						
	EB						
	EC						
	ED						
	EE						
	EF						
	EG						
	EH						
	EI						
	EJ						
	EK						
	EL						
	EM						
	EN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	EN						
	EP						
	EQ						
	ER						
	ES						
	ET						
	EU						
	EV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
EW	Huaichang SUN, et al., "Retrovirus Vector-Mediated Correction and Cross-Correction of Lysosomal α -Mannosidase Deficiency in Human and Feline Fibroblasts", Human Gene Therapy, Vol. 10, pp. 1311-1319, (May 20, 1999)						
EX	Ji REUSER, et al., "Lysosomal storage diseases: cellular pathology, clinical and genetic heterogeneity, therapy", Ann Biol Clin., Vol. 52, (1994), pp. 721-728						
EY							
EZ		<input type="checkbox"/> Additional References sheet(s) attached					
Examiner		Date Considered					

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.